Ornique (Ethinylestradiol, Etonogestrel)

Ethinylestradiol, the active ingredient in Ornique, is a combined combinatorial hormonal contraceptive presented as a tablet for oral use. It is used to prevent pregnancy and to regulate menstrual cycles in women of reproductive age.

GNH USA supplies Ornique as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ornique, a combined hormonal contraceptive, acts on the reproductive endocrine system to prevent pregnancy and manage menstrual disorders. - Contraception: prevention of pregnancy in women of reproductive age. - Menstrual cycle regulation: helps achieve regular menstrual bleeding patterns. - Acne treatment: reduces acne lesions associated with hormonal fluctuations.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient tension‑type headaches. - Breast tenderness: temporary discomfort in breast tissue. - Spotting: irregular vaginal bleeding, especially during the first cycles.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins. - Pulmonary embolism: clot migration to lung arteries. - Stroke or myocardial infarction: rare cerebrovascular or cardiac events. - Severe allergic reaction: anaphylaxis with rash, swelling, or breathing difficulty.

Before using Ornique, consider the following precautions: - Contraindications: known thrombophilia, history of venous thromboembolism, estrogen‑dependent tumor. - Smoking: avoid use in women over 35 who smoke more than 15 cigarettes per day. - Cardiovascular risk: assess hypertension, diabetes, and hyperlipidaemia. - Pregnancy: discontinue immediately if pregnancy is confirmed. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Ornique may interact with several medicines that alter hormone metabolism.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may reduce contraceptive efficacy. - Rifampin therapy: decreases plasma hormone levels, risking breakthrough bleeding. - St. John's wort: herbal inducer that can lower contraceptive effectiveness.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may increase hormone concentrations, raising side‑effect risk. - Macrolide antibiotics (e.g., erythromycin): can elevate plasma levels of etonogestrel. - Selective serotonin reuptake inhibitors: may affect bleeding patterns and require monitoring.